Back

Impact of coronary revascularisation in patients undergoing stress cardiovascular magnetic resonance in primary prevention

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Determinants of outcome following different coronary revascularisation approaches Revascularisation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Antoine Lequipar

Hospital Lariboisiere, Paris (France)

5 More presentations in this session

Presentation thumbnail
Long-term survival after acute myocardial infarction in the UK and South Korea
Professor D. Sim (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
Ten-year outcomes of two-stent versus one-stent strategy for left main bifurcation lesions
Doctor L. Song (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
AI-derived ECG age gap: a novel predictor of mortality after CABG and PCI
Miss L. Vander Heyde (Roeselare, BE)
Abstract Slides Video
Presentation thumbnail
Sex differences in outcomes following percutaneous coronary intervention: results from a comprehensive nationwide registry
Mrs K. Ricken (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Real-world comparison of contemporary drug-coated balloons in acute coronary syndrome
Mr S. Von Koch (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Determinants of outcome following different coronary revascularisation approaches
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Impact of coronary revascularisation in patients undergoing stress cardiovascular magnetic resonance in primary prevention
thumbnail
Congress Presentation
Impact of coronary revascularisation in patients undergoing cardiovascular magnetic resonance for viability assessment
thumbnail
Congress Presentation
Stress computed tomography perfusion versus stress cardiac magnetic resonance for the management of suspected or known coronary artery disease: resources and outcomes impact (STRATEGY II Study)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources